HeartBeam closes $10M public offering of 12.5M shares at $0.80 per share

HeartBeam, Inc.

Issued 12.5M shares at $0.80, gross proceeds $10M; underwriter option for 1.875M additional shares.
Offering led by ClearCardio (first commercial customer), management, board, and existing investors.
Net proceeds to fund commercialization of FDA-cleared synthesized ECG system, extended-wear patch, heart attack detection, AI, and working capital.
Titan Partners Group acted as sole bookrunner; offering closed April 16, 2026.
Common stock (BEAT) and warrants (BEATW) trade on NASDAQ.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HeartBeam, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at approximately $10.0 million (effective 2026-04-14).

Action: entry
Agreement: underwriting
Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
Value: approximately $10.0 million
Effective: 2026-04-14

Exact text from the filing

On April 14, 2026, HeartBeam, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).

View on SEC.gov

Browse all material agreements →

HeartBeam, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-044672

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.